



Original Article

Clinical Characteristics and Survival in Never Smokers With Lung Cancer[☆]

Isaura Parente Lamelas,^{a,*} José Abal Arca,^a Nagore Blanco Cid,^a María Teresa Alves Pérez,^b Raquel Dacal Quintas,^a Hugo Gómez Márquez,^a Rogelio Alejandro García Montenegro,^a Pedro Marcos Velázquez^a

^a Servicio de Neumología, Complejo Hospitalario Universitario de Ourense, Ourense, Spain

^b Unidad de Investigación, Servicio de Medicina Preventiva, Complejo Hospitalario Universitario de Ourense, Ourense, Spain

ARTICLE INFO

Article history:

Received 3 May 2013

Accepted 25 September 2013

Keywords:

Lung cancer
Smokers
Never smokers
Epidemiology
Survival

ABSTRACT

Introduction and objective: To analyse the frequency, clinical characteristics and survival of patients with lung cancer (LC) who have never smoked in comparison to that in patients who smoke.

Patients and methods: A retrospective study in patients diagnosed with LC by cytohistology between 1999 and 2011. Survival was estimated by the Kaplan–Meier method. The χ^2 test was used to estimate the relationship between the variables.

Results: A total of 2161 patients were diagnosed with LC, 396 (18.3%) of whom had never smoked. The mean age (\pm standard deviation) in this group was 72.85 ± 10.52 years; 64.6% were women and 35.4% men. According to the cytohistology, 55.6% were adenocarcinoma, 20.5% squamous cell, 15% small cell, 2.7% large cell, and 6.2% other subtypes. The diagnosis was made in advanced stage (IV) in 61.4%, and 14.4% of the patients received surgical treatment. Survival was 12.4%, with no differences between the two groups. In the group of never smokers, women had better survival than men.

Conclusions: Of the patients diagnosed with LC, 18.3% had never smoked. It was diagnosed mainly in women, at advanced stages and the most common histological type was adenocarcinoma. There were no survival differences compared to the group of smokers.

© 2013 SEPAR. Published by Elsevier España, S.L. All rights reserved.

Características clínicas y supervivencia de los pacientes nunca fumadores con cáncer de pulmón

RESUMEN

Introducción y objetivo: Analizar la frecuencia, las características clínicas y la supervivencia de los pacientes con cáncer de pulmón nunca fumadores comparándolas con los pacientes fumadores.

Pacientes y métodos: Estudio retrospectivo de pacientes diagnosticados de cáncer de pulmón mediante citohistología de 1999 al 2011. Se estimó la supervivencia por el método de Kaplan–Meier. Para estimar la relación entre las variables se usó la prueba de χ^2 .

Resultados: Se diagnosticaron 2.161 pacientes, 396 (18,3%) nunca fumadores. En este grupo la edad media (\pm desviación estándar) fue de $72,85 \pm 10,52$, el 64,6% mujeres y el 35,4% hombres. Según la citohistología, el 55,6% eran adenocarcinoma, el 20,5% epidermoide, el 15% de célula pequeña, el 2,7% de célula grande y el 6,2% otros subtipos. El diagnóstico se hizo en estadio avanzado (IV) en el 61,4% de pacientes, y el 14,4% recibieron tratamiento quirúrgico. La supervivencia fue del 12,4%, sin diferencias entre los 2 grupos. En el grupo de nunca fumadores las mujeres tuvieron mejor supervivencia que los hombres.

Conclusiones: El 18,3% fueron pacientes nunca fumadores. Se diagnosticaron mayoritariamente en mujeres, estadios avanzados y estirpe histológica adenocarcinoma. No hubo diferencias de supervivencia con el grupo de fumadores.

© 2013 SEPAR. Publicado por Elsevier España, S.L. Todos los derechos reservados.

Palabras clave:

Cáncer de pulmón
Fumadores
Nunca fumadores
Epidemiología
Supervivencia

[☆] Please cite this article as: Parente Lamelas I, Abal Arca J, Blanco Cid N, Alves Pérez MT, Dacal Quintas R, Gómez Márquez H, et al. Características clínicas y supervivencia de los pacientes nunca fumadores con cáncer de pulmón. Arch Bronconeumol. 2014;50:62–66.

* Corresponding author.

E-mail address: parentelamelas@gmail.com (I. Parente Lamelas).

Introduction

Lung cancer (LC) is the leading cause of death from cancer worldwide,¹ accounting for 1 527 000 deaths every year.² In Spain alone, every year 20 401 people die of LC, which is the third most common cause of death after ischaemic heart disease and cerebrovascular disease.³ In Spain, the incidence and mortality of LC continue to rise in women, while in men it reached its peak in the 1990s, and is currently on the decline.⁴

It is well known that the main causative factor of LC is tobacco use. Indeed, in countries such as the United States, the fall in smoking rates in the population has been accompanied by a reduction in the incidence and mortality of LC.⁵ However, around 10%–25% of cases of LC occur in never smokers. Even among never smokers, LC remains one of the principal causes of death from cancer⁶ and in non-smoking women it is the third most common cause of cancer death.⁷ In recent years this has led to increased interest in other LC risk factors, such as passive smoking, domestic exposure to radon, previous pulmonary comorbidities and genetic or dietary factors.^{8,9}

Recent studies suggest that LC in never smokers (LCNS) is a distinct entity, to be distinguished both epidemiologically and biologically from LC in smokers.¹⁰ Furthermore, the rise in the non-smoking population throughout the world justifies the interest in determining how LC behaves in these patients. Accordingly, the aim of our study was to analyse the incidence, clinical characteristics and survival of patients with LCNS in comparison to that in patients who smoke.

Patients and Methods

This was an observational, retrospective study of a cohort of LC patients, diagnosed between 1 January 1999 and 31 December 2011 in the University Hospital Complex of Orense. All patients with a primary cytohistological diagnosis of LC were included. Case information was collected from the clinical documentation, bronchoscopy and anatomical pathology databases.

We designed a database for the collection of variables, including identification, age, sex, smoking habit, symptoms, comorbidities, fiberoptic bronchoscopy (FB) findings, diagnostic tests, stage, definitive diagnosis, treatment and date of death. The World Health Organisation (WHO) system was used for histological classification.¹¹ Tumour involvement was classified according to the TNM staging system (7th edition) of the International Association for Study of Lung Cancer (IASLC).¹² Date of death was obtained from the clinical records, or, if it was not recorded, a telephone call was made to the patient's home or the Death Registry of Galicia. Data were censored on 1 October 2012 (last study day). Never smokers were defined as subjects who had smoked less than 100 cigarettes during their lifetime, and ex-smokers were those who had stopped smoking at least 6 months earlier.¹³

Statistical Analysis

A descriptive analysis of the data was performed, with quantitative variables expressed as mean±standard deviation. Qualitative variables were provided as absolute frequencies and percentages. The χ^2 test was used to determine associations between variables. Survival was estimated using the Kaplan–Meier method and the curves obtained were compared with the Mantel–Haenszel log-rank test. Univariate and multivariate analyses were carried out to identify factors related to death, on the basis of the Cox proportional hazards model. A Cox regression model with p-spline smoothing was estimated for the age variable and for testing the non-linearity of this variable. Statistical significance (*P*) was set at .05. The

Table 1

Epidemiological and Clinical Characteristics According to Smoking Habit.

	Smoker	Never smoker	<i>P</i>
<i>Sex</i>			
Men	95.5%	35.4%	<.001
Women	4.5%	64.6%	
<i>Mean age (years)±SD</i>	67.3±11.18	72.85±10.52	<.001
<i>Histology</i>			
Squamous cell	43.3%	20.5%	<.001
Adenocarcinoma	27.5%	55.6%	
Small cell	21.4%	15%	
Large cell	2.8%	2.7%	
Other	5%	6.2%	
<i>Stage</i>			
I, II	20%	17.6%	<.001
IIIA, IIIB	31.7%	21%	
IV	48.3%	61.4%	
<i>Surgery</i>	15.2%	14.4%	.379
<i>Survival</i>	10%	14.1%	.118

SD: standard deviation; other: adenosquamous, undifferentiated, carcinoid; *P*: statistical significance of the comparison.

Statistical Package for Social Sciences version 15.0 (SPSS, Chicago, IL, US) and R Project free software (www.r-project.org/) were used.

Results

Demographic Characteristics

LC was diagnosed in 2161 patients, of which 396 (18%–3%) were LCNS. Of these, 140 (35.4%) were men and 256 (64.6%) women. The principal characteristics of the patients, by smoking habit, are listed in [Table 1](#).

Clinical Characteristics

In the LCNS group, the most frequently observed comorbidities were arterial hypertension (42.6%) and heart disease (19%), and in the smokers, chronic obstructive pulmonary disease (COPD) (42.3%) and arterial hypertension (21%) ([Table 2](#)). The main symptoms in both groups were cough and systemic symptoms ([Table 3](#)). FB was performed in all LCNS patients, and direct and indirect signs of tumour disease were observed under direct vision in 270 (68.2%). LCNS patients were treated with surgery (14.4%), chemotherapy (48.5%), and radiotherapy (23%) and 33.8% were candidates for palliative care only. In 80% of the patients who received radiotherapy, the intent was palliative.

Survival

Five-year survival for the overall study population with LC was 9.37%, with a median of 7.8 months (95% CI: 8.1–10.8). Five-year survival in the never smokers group was 12.4% (median:

Table 2

Comorbidities in Smokers and Never Smokers.

	Smoker (%)	Never smoker (%)	<i>P</i>
COPD	42.3	8.6	<.001
Arterial hypertension	23.2	42.6	<.001
Heart disease	21	18.9	.372
Previous neoplasm	13	11.6	.558
Diabetes	17	16.2	.711
Gastrointestinal	13	12	.561
Previous pneumonia	9.5	8.1	.442

COPD: chronic obstructive pulmonary disease; *P*: statistical significance of the comparison.

Download English Version:

<https://daneshyari.com/en/article/4205683>

Download Persian Version:

<https://daneshyari.com/article/4205683>

[Daneshyari.com](https://daneshyari.com)